CLINICAL_TRIALS ClinicalTrials.gov record update

Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05043571
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:30.598319+00:00
Published At: 2021-09-14T00:00:00+00:00
Record Updated At: 2021-09-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Leukemia", "Lymphoblastic Leukemia, Acute Adult", "Lymphoblastic Leukemia in Children", "CAR", "CAR T-Cell-Related Encephalopathy Syndrome", "Refractory Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-09-14"
protocolSection.identificationModule.nctId: "NCT05043571"
protocolSection.identificationModule.officialTitle: "Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.